MARKET

VALN

VALN

Valneva Se
NASDAQ
7.92
-0.04
-0.44%
Closed 16:00 03/28 EDT
OPEN
7.92
PREV CLOSE
7.96
HIGH
8.00
LOW
7.73
VOLUME
4.63K
TURNOVER
0
52 WEEK HIGH
17.05
52 WEEK LOW
6.58
MARKET CAP
549.60M
P/E (TTM)
-4.9034
1D
5D
1M
3M
1Y
5Y
Buy Rating on Valneva Supported by Promising Vaccine Developments and Solid Revenue Projections
TipRanks · 2d ago
Valneva SE Files Key Financial Documents for 2023
TipRanks · 2d ago
Valneva Announces The Initiation Of Phase 1 Trial Of Second-Generation Zika Vaccine Candidate
The randomized, placebo-controlled, Phase 1 trial, VLA1601-102, is planned to enroll approximately 150 participants aged 18 to 49 years in the United States. Topline data from the trial are expected in the first half of 2025. Participants will receive a low, medium or high dose of VLA 1601.
Benzinga · 2d ago
Weekly Report: what happened at VALN last week (0318-0322)?
Weekly Report · 3d ago
Valneva Is Maintained at Buy by Guggenheim
Dow Jones · 6d ago
Valneva Price Target Cut to $17.00/Share From $18.00 by Guggenheim
Dow Jones · 6d ago
What Analysts Are Saying About Valneva Stock
Valneva (NASDAQ:VALN) underwent analysis by 4 analysts in the last quarter. The average price target for Valneva is $23.75. The company is a vaccine company focused on developing life-saving vaccines. The analysts have provided 12-month price targets of $26.00 for the company.
Benzinga · 6d ago
Guggenheim Maintains Buy on Valneva, Lowers Price Target to $17
Benzinga · 6d ago
More
About VALN
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

Webull offers Valneva SE stock information, including NASDAQ: VALN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VALN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VALN stock methods without spending real money on the virtual paper trading platform.